58 results about "Hepatitis B virus DNA" patented technology

This invention provides substituted benzimidazole compounds shown in common formula (I) and their pharmacologically permitted salts. The definitions of R1, R2, R3, R4 and n in common formula (I) are mentioned in the instruction. Pharmacological experiments show that, this kind of compounds and their pharmacologically permitted salts or their solvates or hydrates perform excellent anti-hepatitis B virus (anti-HBV) activities and are especially inhibitory to DNA replication of HBV. They are thus promising as anti-HBV drugs. This invention also provides a method to prepare this kind of compounds.

The invention relates to a nested quantitative PCR detection method for virus covalently closed circular DNA (ccc DNA) of hepatitis b virus. The particular detection steps are: 1) extraction DNA of hepatitis b virus; 2) design and synthesis primers and probe: design an internal and an external primer at conservative region of both sides of negative chain gap of HVB DNA, with Taqman fluorescence probe arranged at the lower part of the negative chain gap; 3) Plasmid-SafeTM ATP-Dependent DNase restriction enzyme purification; 4) nested real time quantitative PCR amplification, comprising: common PCR-template with external primer amplification purification and real time quantitative PCR-fluorescence quantitative amplification to common PCR production with internal primer and fluorescence probe. The invention can improve the specificity and sensitivity of detection reactive to make the operation process and result analysis much more accurate, simple and time saving.

The invention relates to a detecting method and a reagent box for the DNA of the hepatitis B viruses of wild type and G1896A mutant, in particular to a method for detecting the DNA of the hepatitis B viruses of wild type and G1896A mutant by using the technology of combining the Locked Nucleic Acids with a molecular beacon probe as well as a real time PCR method and a reagent box used for finishing the detection. The method of the invention can specially and sensitively detect the DNA of the hepatitis B viruses of wild type and G1896A mutant in a clinic blood sample.

The invention provides a HBV nucleic acid quantitative detection system based on a micro-droplet digital PCR technology, the HBV nucleic acid quantitative detection system comprises an upstream primerand a downstream primer for amplifying hepatitis B virus DNA, a specific probe for detecting the hepatitis B virus DNA; a non-infected linearizing double-stranded plasmid quality control standard product and a probe for detecting the quality control standard product; and a buffer system comprising deoxyribonucleoside triphosphates dATP, dCTP, dGTP, and dUTP, and UNG. The HBV nucleic acid quantitative detection system is based on the micro-droplet digital PCR technology to realize the accurate absolute quantification of HBV DNA, faces the clinical actual demand, and has an important application prospect.

The invention belongs to the technical field of molecular biology, and discloses a method for qualitatively and quantificationally detecting the DNA (deoxyribonucleic acid) of hepatitis B virus by using a DNAzyme probe. The method is characterized in that specific to the limitations of the prior art, the single-step qualitative and quantificational detection of the hepatitis B virus is realized by using PCR (Polymerase Chain Reaction) amplification as a basic detection platform and introducing the 3'-amino modified DNAzyme probe. The method has the advantages of high sensitivity, strong specificity, wide detection linearity range, low cost, high accuracy, convenient operation and the like. A simple, rapid, accurate, high-efficiency, economic and practical detection method is supplied for the hepatitis B virus.

An oligonucleotide chip for detecting the mutation sites of hepatitis B virus is composed of glass substrate, oligonucleotide probes array and reference point-type coated laeyr. The said probes arrayhas 72 probes, including 12 known mutation sites and relative wild sites. The process for detcting mutation sites of hepatitis B virus includes such steps as mixing the probes as solid primer, hepatitis B virus DNA and template, and three pairs of liquid primers, PCR amplification via fluorescence labeled Cy3-dCTP, and analyzing mutation sites according to intensity of fluorescent signal. Its advantages are high speed, efficiency and correctness.

The invention discloses an extraction method of hepatitis B virus deoxyribonucleic acid (DNA) and belongs to the field of nucleic acid extraction in molecular biology. An alkaline lysis technology is adopted according to particular characteristics of blood and viruses; impurities such as proteins, polysaccharides, lipids and the like are not required to be pre-removed; and the virus DNA is directly extracted through lysis buffer 1 and lysis buffer 2. The method has the characteristics of high efficiency, high speed, simplicity and no pollution, and the whole operation process only lasts for 50 minutes. The obtained hepatitis B virus DNA can be applied to molecular biology experiments such as the common polymerase chain reaction (PCR), fluorescence quantitative PCR and the like.

The invention discloses an electrochemiluminescence sensor for detecting hepatitis B virus DNA and preparation and application thereof. The electrochemiluminescence sensor is constructed based on an aggregation-induced electrochemiluminescence body, a toehold-mediated strand displacement reaction (TSDR) and a CRISPR/Cas12a system. A Zr-ETTC@ Fc-SP compound is prepared and fixed to the surface of an electrode, and an ECL signal of Zr-ETTC can be quenched by Fc; a TSDR system is constructed by using a target substance T chain, an A-B compound and a single chain C, and a displacement reaction is carried out to obtain a large amount of Cas12a activator; and the Cas12a-crRNA compound can recognize the Cas12a activator, activate the cleavage activity of the Cas12a activator and perform trans-cleavage on SP, so that Fc is separated from the surface of the electrode, the ECL signal is recovered, and HBV DNA detection is realized. The HBV DNA detection method disclosed by the invention has the advantages of high sensitivity, strong stability, good reproducibility, high reaction speed and the like.

The invention relates to the technical field of biomedicines. The currently reported hepatitis B virus vaccine mainly comprises one or several of HBsAg, preS 1, preS2 and HBcAg, some cell factor genes with immunological enhancement function or lymphocyte epitope genes and the like, however, the immunoprophylaxis effect and treatment effect of the vaccine are always unsatisfactory. The invention provides a hepatitis B vaccine which comprises hepatitis B virus surface antigen gene HBsAg, core protein gene HBc and e-antigen gene, also comprises a human microRNA181a precursor gene sequence, and can assist stimulating the body immunity pathway. The construction process of the vaccine relates to PCR, enzyme cutting, connection, conversion and other molecularly biological operating means. The hepatitis B vaccine has the advantages of effectively activating the body to produce a specific antibody against the hepatitis B virus, stimulating body cell immunity and secreting various cell factors. Therefore, the aim of treating chronic hepatitis B is fulfilled.

The invention relates to 5-o-substitued phenyl propionyl quinic acid compounds and pharmaceutical application thereof, specifically 5-o-[3-substitued phenyl propionyl] quinic acid compounds having the formula of (I) and anti-hepatitis B virus activity and pharmaceutical salts thereof. The invention also relates to a preparation method of the quinic acid compounds, pharmaceutical application thereof, and drugs and pharmaceutical compositions containing the quinic acid compounds. The compounds having the formula of (I) and pharmaceutical salts thereof inhibit hepatitis B virus DNA (HBVDNA) replication and reduces hepatits B virus surface antigen (HBsAg) expression thereby to have prospect pharmaceutical application in the preparation of a drug for treating correlated hepatitis B virus infectious disease.

A peptide nucleic acid chip for detecting the mutation sites of hepatitis B virus is composed of glass substrate or nylon film, peptide nucleic acid probes array and reference point-type coated layer. Its preparing process includes PCR amplification of hepatitis B virus DNA speciment, fluorescence labelling, and hybridization. The mutation sites can be determined according to the intensity of hybrid signals. Its advantages are high speed, high effect, and high correctness.

The present invention relates to a method for quantifying hepatitis B virus DNA (HBA-DNA) by means of the PCR hybridization process, and to primers and probes used for such method. The present invention also relates to a kit for detecting HBV-DNA comprising said primers and probes. Specifically, the present invention is characterized in that said HBV is either an adr sub-type or an adw sub-type.

The invention relates to a kit for detecting product DNA of hepatitis B virus DNA amplified through a loop-mediated isothermal nucleic acid amplification technology by using gold nanoparticles, belonging to the technical field of biological detection. In combination with the loop-mediated isothermal nucleic acid amplification technology and a biological nanotechnology, the invention has the advantages that the sensitivity of biological molecular detection is improved, the operation of the method is simple, the detection is rapid, the accuracy is high, special instruments and devices are not required, and the kit can be widely used for high-sensitivity hepatitis B virus detection in fields such as family diagnosis, clinical diagnosis, infectious disease control, environmental monitoring, inspection and quarantine, biotechnology and the like. The kit comprises: (1) gold nanoparticles labeled with molecular probes capable of identifying specific sequences of hepatitis B viruses; and (2) a loop-mediated isothermal nucleic acid amplification system capable of amplifying hepatitis B virus DNA in a sample to be detected or capable of amplifying hepatitis B virus RNA in the sample to be detected after reverse transcription.

The invention discloses a nucleic acid releasing agent and a hepatitis B virus nucleic acid releasing method. The nucleic acid releasing agent comprises 0.02 to 0.2 vol.% of Gemini quaternary ammoniumsalt surfactant, 50 to 300 mM of potassium hydroxide, isopropanol (0.2-2 mL/100 mL), and the balance being sterile water. The nucleic acid releasing agent with a trace amount can rapidly destroy theprotein structure of the shell of pathogen, encloses and precipitates substances that can influence the PCR amplification such as serum proteins, and makes HBV DNA carry out complexing so as to completely precipitate out HBV DNA. The releasing agent is safe to use, the operation is simple and convenient, and the manufacturing cost is low. The releasing agent is used to release HBV DNA of a serum,blood plasma, or whole blood sample without heating or centrifugation; only through one-step sample loading, DNA can be released and extracted. According to the method, HBV nucleic acid extraction andamplification-fluorescence PCR quantitative detection can be carried out in one step, and the problems of loss and contamination of nucleic acid in a multi-step nucleic acid extraction method are solved.

The invention relates to 1-o-[3-aryl substituted-acrylyl]quinic acid compounds having the formula of (I), and an application thereof. The invention also relates to a preparation method of the quinic acid compounds, and intermediate compounds (II) of the quinic acid compound, i.e. 1-o-[3-aryl substituted-acrylyl]-3,4-o-isopropylidene quinic acid-1.5-lactone. The invention relates to pharmaceutical application of the quinic acid compounds, and pharmaceutical compositions containing the same. The compounds having the formula (I) and the compounds having the formula of (II), and pharmaceutical salts thereof have the effects of inhibiting hepatitis B virus DNA replication and reducing hepatitis B virus surface antigen expression. Thus, the compounds having the formula of (I) and the compounds having the formula of (II) have pharmaceutical prospect application in the preparation of a drug for preventing and treating hepatitis B virus infectious disease.

This invention relates to anti-viral drugs such as Helioxanthin and its analogs. The present compounds may be used alone or in combination with other drugs for the treatment of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, Japanese Encephalitis, West Nile virus and related flaviviruses. In addition, compounds according to the present invention can be used to prevent hepatoma secondary to virus infection as well as other infections or disease states which are secondary to the virus infection.

The invention provides a primer probe group for detecting hepatitis B virus based on RAA fluorescence method, and belongs to the technical field of molecular biological detection. The primer probe group comprises an upstream primer, a downstream primer and a probe, wherein the nucleotide sequence of the upstream primer is shown by SEQ ID NO.1, the nucleotide sequence of the downstream primer is shown by SEQ ID NO.2, and the nucleotide sequence of the probe is shown by SEQ ID NO.3; the probe is a modified by a fluorescence reporter group and a fluorescence quenching group. By adopting the primer probe group provided by the invention, detection of the hepatitis B virus DNA can be finished within 15min, high temperature is not required for DNA unwinding, and the detection can be finished simply by performing isothermal amplification at 30-42 DEG C; moreover, the detection is fast and sensitive and has high specificity while avoiding false positive.

The invention relates to a double mutation detection method and a reagent box for a hepatitis B virus DNA A1762T-G1764A, in particular to a double mutation detection method for detecting the A1762T-G1764A, in the DNA sequence of the hepatitis B virus by utilizing a molecular beacon probe technology and a real time PCR method as well as a reagent box for finishing the detection. The method of the invention can specially and sensitively detect the double mutation hepatitis B virus DNA of the A1762T-G1764A in a clinic blood sample.

The invention discloses a probe and a fluorescence sensor for quantitatively detecting hepatitis B virus DNA and a method. The fluorescence sensor comprises a first probe enhanced sequence G-rich and a second probe DNA silver nanocluster sequence AgNCs-HBV, the G-rich and the AgNCs-HBV dissolve in a buffer solution, a target substance to be detected is added, mixed incubation is performed, a fluorescence reaction system is constructed, fluorescence detection is performed, and a fluorescence signal can be obtained. The fluorescence sensor provided by the invention realizes high-sensitivity detection of HBV based on a silver nano-cluster beacon, can improve the detection speed by tuning DNA silver nano-cluster sequence AgNCs-HBV fluorescence through the proximity enhancement sequence G-rich, is low in synthesis cost, can overcome the limitation of the traditional PCR method for detecting HBV on site and personnel requirements, is good in universality, stability and reproducibility, and is suitable for large-scale screening or quantitative detection of the hepatitis B HBV in communities or hospitals.

The invention discloses a kit for detecting the sensitivity of an individual patient to Lamivudine drugs. The kit comprises a specific primer pair and DNA sequencing primer for detecting the YMDD region gene type of the DNA of hepatitis B in vivo of a patient, a PCR reaction assembly, a PCR product purification assembly, a DNA sequencing reaction assembly and the like. The kit is used for analyzing and evaluating the sensitivity of the patient to the Lamivudine drugs.

The invention discloses application of icariside II in preparing anti-hepatitis-B-virus products. Research results of in-vitro hepatitis B virus infected cell model experiments show that icariside IIcan inhibit expression of hepatitis B virus surface antigen and e antigen and can inhibit copying of hepatitis B virus DNA; in-vivo researches through a HBV infected mouse model show that icariside IIcan lower HBsAg, HBeAg and HBVDNA levels in HBV infected mouse serum. It is proved that icariside II has obvious anti-hepatitis-B-virus effect and can be used for preparing drug resistant to relateddiseases caused by hepatitis B virus infection.